Literature DB >> 9879742

Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system.

C M Ferrario1, S N Iyer.   

Abstract

Accumulating evidence suggests that angiotensin-(1-7) [Ang-(1-7)] is an important component of the renin-angiotensin system. As the most pleiotropic metabolite of angiotensin I (Ang I) it manifest actions which are most often the opposite of those described for angiotensin II (Ang II). Ang-(1-7) is produced from Ang I bypassing the prerequisite formation of Ang II. The generation of Ang-(1-7) is under the control of at least three enzymes, which include neprilysin, thimet oligopeptidase, and prolyl oligopeptidase depending on the tissue compartment. Both neprilysin and thimet oligopeptidase are also involved in the metabolism of bradykinin and the atrial natriuretic peptide. Moreover, recent studies suggest that in addition to Ang I and bradykinin, Ang-(1-7) is an endogenous substrate for angiotensin converting enzyme. This suggests that there is a complex relationship between the enzymatic pathways forming angiotensin II and other various vasodepressor peptides from either the renin-angiotensin system or other peptide systems. The antihypertensive actions of angiotensin-(1-7) are mediated by an angiotensin receptor that is distinct from the pharmacologically characterized AT1 or AT2 receptor subtypes. Ang-(1-7) mediates it antihypertensive effects by stimulating synthesis and release of vasodilator prostaglandins, and nitric oxide and potentiating the hypotensive effects of bradykinin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879742     DOI: 10.1016/s0167-0115(98)00134-7

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  16 in total

Review 1.  The role of the nervous system in hypertension.

Authors:  J M Wyss; S H Carlson
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Distribution of peptidase activity in teleost and rat tissues.

Authors:  N Agirregoitia; R Laiz-Carriòn; A Varona; M P Martín Del Rio; J M Mancera; J Irazusta
Journal:  J Comp Physiol B       Date:  2005-07-26       Impact factor: 2.200

Review 3.  Angiotensin receptor-associated proteins: local modulators of the renin-angiotensin system.

Authors:  Hayo Castrop
Journal:  Pflugers Arch       Date:  2012-05-16       Impact factor: 3.657

Review 4.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

5.  Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.

Authors:  Hiroyuki Shimoura; Hidekazu Tanaka; Kensuke Matsumoto; Yasuhide Mochizuki; Yutaka Hatani; Keiko Hatazawa; Hiroki Matsuzoe; Junichi Ooka; Hiroyuki Sano; Takuma Sawa; Yoshiki Motoji; Keiko Ryo-Koriyama; Ken-Ichi Hirata
Journal:  Heart Vessels       Date:  2016-10-08       Impact factor: 2.037

6.  Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line.

Authors:  Kenji Oki; Phillip G Kopf; William B Campbell; Milay Luis Lam; Takeshi Yamazaki; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-12-07       Impact factor: 4.736

7.  Role of Mas Receptor Antagonist A799 in Renal Blood Flow Response to Ang 1-7 after Bradykinin Administration in Ovariectomized Estradiol-Treated Rats.

Authors:  Aghdas Dehghani; Shadan Saberi; Mehdi Nematbakhsh
Journal:  Adv Pharmacol Sci       Date:  2015-09-03

Review 8.  A systematic review to investigate whether Angiotensin-(1-7) is a promising therapeutic target in human heart failure.

Authors:  Vincent C H Lee; Elizabeth N Lloyd; Helena C Dearden; Kenneth Wong
Journal:  Int J Pept       Date:  2013-12-12

Review 9.  New angiotensins.

Authors:  Jasmina Varagic; Aaron J Trask; Jewell A Jessup; Mark C Chappell; Carlos M Ferrario
Journal:  J Mol Med (Berl)       Date:  2008-04-25       Impact factor: 4.599

10.  Angiotensin-(1-7) abrogates angiotensin II-induced proliferation, migration and inflammation in VSMCs through inactivation of ROS-mediated PI3K/Akt and MAPK/ERK signaling pathways.

Authors:  Feng Zhang; Xingsheng Ren; Mingxia Zhao; Bing Zhou; Ying Han
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.